We scan new podcasts and send you the top 5 insights daily.
Cyclodextrin therapeutics fail to absorb into systemic circulation through the gastrointestinal tract regardless of modifications made to their structure. Consequently, developers must design programs from the outset around subcutaneous injections, self-administered pens, or osmotic pumps rather than attempting oral delivery formulations.
In selecting targets for its macrocyclic peptide platform, Merck strategically prioritizes two factors: 1) extracellular targets that don't require difficult cell penetration, and 2) disease areas where existing options are only injectable. This creates a clear path to differentiation and addresses high unmet patient needs.
To tackle the high-risk, high-reward obesity market, the company is developing both an injectable and an oral version of the same triple-agonist molecule. The injectable version will enter the clinic first, allowing them to quickly obtain human proof-of-concept and validate the molecule's efficacy before investing heavily in the more complex oral formulation.
The intravenous amivantamab regimen has faced adoption challenges due to practical burdens on patients and clinics, including long infusion times, infusion reactions, and scheduling difficulties. The shift to a subcutaneous formulation is a critical step to overcome these non-clinical barriers.
Pharma teams often fear changing formulations late in development due to perceived regulatory hurdles. However, the path, which involves a relative bioavailability study to bridge the old and new formulations, is a well-established and manageable process if key safety and efficacy metrics are maintained.
David Ricks highlights that oral peptide GLP-1s achieve only about 1% bioavailability due to gut acid breakdown, requiring bioprocess manufacturing. In contrast, chemically derived small molecules like Lilly's achieve 50% to 80% bioavailability. While synthesizing a GPCR agonist chemically without off-target effects is technically difficult, chemical synthesis offers far lower production costs and vastly easier scale.
Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.
A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.
Cyclodextrin dimers sit between 2,000 and 3,000 Daltons, functioning like therapeutic antibodies by sequestering targets without metabolic transformation. Despite exceeding classical size boundaries, they are synthesized via stepwise chemistry and handled by FDA CDER under small molecule regulatory expectations.
New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.
In amorphous solid dispersions, drug developers often reduce polymer content to increase the active drug percentage. This is a critical mistake, as the polymer actively enhances absorption. Less polymer can lead to poorer bio-performance, negating the benefit of a higher drug load.